相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Daratumumab induces mechanisms of immune activation through CD38+NK cell targeting
Domenico Viola et al.
LEUKEMIA (2021)
Systemic administration of IL-33 induces a population of circulating KLRG1hitype 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma
Camille Guillerey et al.
IMMUNOLOGY AND CELL BIOLOGY (2021)
Identification of human cytotoxic ILC3s
Lisette Krabbendam et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
Elotuzumab in the treatment of relapsed and refractory multiple myeloma
Sebastian Grosicki et al.
FUTURE ONCOLOGY (2021)
Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan
Keiichi Akizuki et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
Tatiana Pazina et al.
CANCERS (2021)
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
Almudena Garcia-Ortiz et al.
CANCERS (2021)
Molecular dynamics of targeting CD38 in multiple myeloma
Fabio Malavasi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Natural killers or ILC1s? That is the question
Cyril Seillet et al.
CURRENT OPINION IN IMMUNOLOGY (2021)
Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels
Jiayan Gu et al.
CYTOKINE (2021)
Ontogeny and heterogeneity of innate lymphoid cells and the noncoding genome*
Michael F. Michieletto et al.
IMMUNOLOGICAL REVIEWS (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Myeloma natural killer cells are exhausted and have impaired regulation of activation
Criselle D'Souza et al.
HAEMATOLOGICA (2021)
Neuroimmune Interactions and Rhythmic Regulation of Innate Lymphoid Cells
Nicolas Jacquelot et al.
FRONTIERS IN NEUROSCIENCE (2021)
Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment
Benjamin Motais et al.
CELLS (2021)
Therapeutic manipulation of innate lymphoid cells
Laura M. Cobb et al.
JCI INSIGHT (2021)
Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver
Chiara Di Censo et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2021)
Conventional NK cells and tissue-resident ILC1s join forces to control liver metastasis
Laura Ducimetiere et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma
Alejandra Leivas et al.
BLOOD CANCER JOURNAL (2021)
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Faroogh Marofi et al.
STEM CELL RESEARCH & THERAPY (2021)
Optimising NK cell metabolism to increase the efficacy of cancer immunotherapy
Chloe Choi et al.
STEM CELL RESEARCH & THERAPY (2021)
Vitamin D and Exercise Are Major Determinants of Natural Killer Cell Activity, Which Is Age- and Gender-Specific
Sooyeon Oh et al.
FRONTIERS IN IMMUNOLOGY (2021)
Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
Margaux Lejeune et al.
CANCERS (2021)
FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma
Austin B. Bigley et al.
BLOOD ADVANCES (2021)
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
Lisa C. Holthof et al.
HEMASPHERE (2021)
CAR T and CAR NK cells in multiple myeloma: Expanding the targets
Urvi A. Shah et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2020)
Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
Huang Zhu et al.
BLOOD (2020)
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide
Subhashis Sarkar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
'Off-the-shelf' allogeneic CAR T cells: development and challenges
S. Depil et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Multiple myeloma: 2020 update on diagnosis, risk-stratification and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Innate lymphoid cells control signaling circuits to regulate tissue-specific immunity
Christoph S. N. Klose et al.
CELL RESEARCH (2020)
Multiple Myeloma Incidence and Mortality Around the Globe; Interrelations Between Health Access and Quality, Economic Resources, and Patient Empowerment
Heinz Ludwig et al.
ONCOLOGIST (2020)
CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity
Meisam Naeimi Kararoudi et al.
BLOOD (2020)
Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor
Shijie Wang et al.
ONCOLOGY LETTERS (2020)
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
Silvia Pesce et al.
CANCERS (2020)
FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma
Jode P. Goodridge et al.
BLOOD (2020)
Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
Helmi Alfarra et al.
FRONTIERS IN IMMUNOLOGY (2020)
Plasticity of innate lymphoid cell subsets
Suzanne M. Bal et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life
Christine Greil et al.
HAEMATOLOGICA (2019)
The Tumor Microenvironment Innately Modulates Cancer Progression
Dominique C. Hinshaw et al.
CANCER RESEARCH (2019)
IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma
Jian Wu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
What Defines NK Cell Functional Fate: Phenotype or Metabolism?
Sophie M. Poznanski et al.
FRONTIERS IN IMMUNOLOGY (2019)
Probiotics Lactobacillus reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells
Tingting Wang et al.
FRONTIERS IN IMMUNOLOGY (2019)
Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions
Francesca Romana Merlotti et al.
FRONTIERS IN IMMUNOLOGY (2019)
IL-13 secreted by ILC2s promotes the self-renewal of intestinal stem cells through circular RNA circPan3
Pingping Zhu et al.
NATURE IMMUNOLOGY (2019)
Interferon γ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells
Dorina Ujvari et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells
Yufeng Wang et al.
CLINICAL CANCER RESEARCH (2018)
Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies
Roman Hajek et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Interferon-gamma in mobilized stem cells: A possible prognostic marker in early post-transplant management in multiple myeloma
Leticia Navarro Gordan Ferreira Martins et al.
CYTOKINE (2018)
NKp46 Calibrates Tumoricidal Potential of Type 1 Innate Lymphocytes by Regulating TRAIL Expression
Gleb Turchinovich et al.
JOURNAL OF IMMUNOLOGY (2018)
Activating and inhibitory receptors expressed on innate lymphoid cells
Sophie Guia et al.
SEMINARS IN IMMUNOPATHOLOGY (2018)
Innate Lymphoid Cells: 10 Years On
Eric Vivier et al.
CELL (2018)
Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease
Danny W. Bruce et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
PD-1 regulates KLRG1+ group 2 innate lymphoid cells
Samuel Taylor et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Enhanced circulating ILC2s and MDSCs may contribute to ensure maintenance of Th2 predominant in patients with lung cancer
Yumin Wu et al.
MOLECULAR MEDICINE REPORTS (2017)
The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation
Antonia Wallrapp et al.
NATURE (2017)
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis
Sara Trabanelli et al.
NATURE COMMUNICATIONS (2017)
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
Brent A. Williams et al.
ONCOTARGET (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
Regulatory Innate Lymphoid Cells Control Innate Intestinal Inflammation
Shuo Wang et al.
CELL (2017)
Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease
Jarrod A. Dudakov et al.
BLOOD (2017)
Developmental options and functional plasticity of innate lymphoid cells
Ai Ing Lim et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Mattias Carlsten et al.
CLINICAL CANCER RESEARCH (2016)
IL-12 drives functional plasticity of human group 2 innate lymphoid cells
Ai Ing Lim et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Intratumorally Establishing Type 2 Innate Lymphoid Cells Blocks Tumor Growth
Juyang Kim et al.
JOURNAL OF IMMUNOLOGY (2016)
Glial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence
Sales Ibiza et al.
NATURE (2016)
Intestinal epithelial tuft cells initiate type 2 mucosal immunity to helminth parasites
Francois Gerbe et al.
NATURE (2016)
The heterogeneity of human CD127+ innate lymphoid cells revealed by single-cell RNA sequencing
Asa K. Bjorklund et al.
NATURE IMMUNOLOGY (2016)
ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation
Claire Pearson et al.
ELIFE (2016)
Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution
L. Rosinol et al.
BONE MARROW TRANSPLANTATION (2015)
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B. Paiva et al.
LEUKEMIA (2015)
The biology of innate lymphoid cells
David Artis et al.
NATURE (2015)
Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs
Georg Gasteiger et al.
SCIENCE (2015)
Innate lymphoid cells: A new paradigm in immunology
Gerard Eberl et al.
SCIENCE (2015)
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Wen-Chi Yang et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Clinical significance of interleukin-22 in multiple myeloma
George Tsirakis et al.
HEMATOLOGY (2015)
The brave new world of innate lymphoid cells
Gérard Eberl et al.
NATURE IMMUNOLOGY (2014)
BAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma
L. Bolkun et al.
ANNALS OF HEMATOLOGY (2014)
Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease
J. Marius Munneke et al.
BLOOD (2014)
MHCII-Mediated Dialog between Group 2 Innate Lymphoid Cells and CD4+ T Cells Potentiates Type 2 Immunity and Promotes Parasitic Helminth Expulsion
Christopher J. Oliphant et al.
IMMUNITY (2014)
Transfection of chimeric anti-CD 138 gene enhances natural killer cell activation and killing of multiple myeloma cells
Hua Jiang et al.
MOLECULAR ONCOLOGY (2014)
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
J. Chu et al.
LEUKEMIA (2014)
Intraepithelial Type 1 Innate Lymphoid Cells Are a Unique Subset of IL-12-and IL-15-Responsive IFN-γ-Producing Cells
Anja Fuchs et al.
IMMUNITY (2013)
5 Immune system: a double-edged sword in cancer
Bodduluru Lakshmi Narendra et al.
INFLAMMATION RESEARCH (2013)
Human type 1 innate lymphoid cells accumulate in inflamed mucosa! tissues
Jochem H. Bernink et al.
NATURE IMMUNOLOGY (2013)
Monitoring NK cell activity in patients with hematological malignancies
Sebastien Viel et al.
ONCOIMMUNOLOGY (2013)
Innate Lymphoid Cells: Emerging Insights in Development, Lineage Relationships, and Function
Hergen Spits et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
Don M. Benson et al.
BLOOD (2012)
Interleukin-22 Protects Intestinal Stem Cells from Immune-Mediated Tissue Damage and Regulates Sensitivity to Graft versus Host Disease
Alan M. Hanash et al.
IMMUNITY (2012)
The Transcription Factor GATA3 Controls Cell Fate and Maintenance of Type 2 Innate Lymphoid Cells
Thomas Hoyler et al.
IMMUNITY (2012)
A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells
Li Lin et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
The role of natural killer cells in immunity against multiple myeloma
James Godfrey et al.
LEUKEMIA & LYMPHOMA (2012)
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Sergei I. Grivennikov et al.
NATURE (2012)
Interleukin-22 Drives Endogenous Thymic Regeneration in Mice
Jarrod A. Dudakov et al.
SCIENCE (2012)
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29 (2011)
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
Don M. Benson et al.
BLOOD (2011)
Cancer-stromal interactions Role in cell survival, metabolism and drug sensitivity
Wan Zhang et al.
CANCER BIOLOGY & THERAPY (2011)
Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4
Dawn Holt et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Novel Role for STAT3 in Transcriptional Regulation of NK Immune Cell Targeting Receptor MICA on Cancer Cells
Romain Bedel et al.
CANCER RESEARCH (2011)
Interaction of tumor cells with the microenvironment
Hendrik Ungefroren et al.
CELL COMMUNICATION AND SIGNALING (2011)
Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression
Brian F. Zamarron et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2011)
IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease
Alessandra Geremia et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
New ways to turn on NKT cells
Dale Ian Godfrey et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
CD28 Expressed on Malignant Plasma Cells Induces a Prosurvival and Immunosuppressive Microenvironment
Jayakumar R. Nair et al.
JOURNAL OF IMMUNOLOGY (2011)
PGE2 inhibits natural killer and γδ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling
Ludovic Martinet et al.
BIOCHEMICAL PHARMACOLOGY (2010)
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells
Teru Hideshima et al.
BLOOD (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma
Rao H. Prabhala et al.
BLOOD (2010)
Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked
Marie von Lilienfeld-Toal et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Clinical Use of Interferon-gamma
Catriona H. T. Miller et al.
CYTOKINE THERAPIES: NOVEL APPROACHES FOR CLINICAL INDICATIONS (2009)
Regulation of multiple myeloma survival and progression by CD1d
Emmanouil Spanoudakis et al.
BLOOD (2009)
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
Alessandra Soriani et al.
BLOOD (2009)
Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells
Don M. Benson et al.
BLOOD (2009)
Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: Implications for tumor evasion of T and NK cells
Monica Bernal et al.
HUMAN IMMUNOLOGY (2009)
Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms
Xiaoyu Hu et al.
IMMUNOLOGICAL REVIEWS (2008)
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma
Masahisa Jinushi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
Yasser M. El-Sherbiny et al.
CANCER RESEARCH (2007)
Tyrosine kinase receptor RET is a key regulator of Peyer's Patch organogenesis
Henrique Veiga-Fernandes et al.
NATURE (2007)
Cytokine-driven regulation of NK cell functions in tumor immunity: Role of the MICA-NKG2D system
Norberto W. Zwirner et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2007)
Immunodeficiency and immunotherapy in multiple myeloma
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
IL-23 promotes tumour incidence and growth
John L. Langowski et al.
NATURE (2006)
Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma
C Fauriat et al.
LEUKEMIA (2006)
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
M Kortylewski et al.
NATURE MEDICINE (2005)
IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3
N Tsuyama et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment
M Perez-Andres et al.
LEUKEMIA (2005)
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
E Carbone et al.
BLOOD (2005)
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
TH Wang et al.
NATURE MEDICINE (2004)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Inflammation and cancer: back to Virchow?
F Balkwill et al.
LANCET (2001)
Cross talk between interferon-γ and -α/β signaling components in caveolar membrane domains
A Takaoka et al.
SCIENCE (2000)
CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes
M Exley et al.
IMMUNOLOGY (2000)
分享论文
